Formycon AG (XTRA: FYB)
Health Care · Biotechnology · DE
€19.46
+2.10% today · -19.9% 1Y
Formycon AG (XTRA: FYB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $384.18M and employs 196 people.
Over the last twelve months the share price has lost 19.9%, trading between 15.80 and 26.95.
Tweenvest scores Formycon AG across four factors: quality 60/100, value 59/100, growth 33/100. Its strongest factor is quality.
FYB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $384.18M
- Revenue (TTM)
- $69.97M
- P/E
- —
- EPS
- -1.42
- Dividend yield
- —
- Beta (5Y)
- 0.70
- 52-week high
- €26.95
- 52-week low
- €15.80
- Avg volume (3M)
- —
- Shares outstanding
- 17.67M
- Employees
- 196
- Next earnings
- —
About Formycon AG
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.
- ISIN
- DE000A1EWVY8
- Founded
- 1999
- Listed since
- Jan 4, 2011
- Exchange
- XETRA Trading Platform
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $393.24M | $7.26 | -2.81% |
| Arcturus Therapeutics Holdings Inc.NasdaqGM: ARCT | $390.53M | $12.61 | -8.22% |
| vTv Therapeutics Inc.NasdaqCM: VTVT | $387.40M | $30.46 | -2.31% |
| Opus Genetics, Inc.NasdaqCM: IRD | $386.03M | $4.64 | -0.22% |
| Kyverna Therapeutics, Inc.NasdaqGS: KYTX | $384.05M | $6.21 | -2.82% |
| Zura Bio LimitedNasdaqCM: ZURA | $383.32M | $4.00 | 0.00% |
| Heartseed Inc.TSE: 219A | $381.84M | ¥2,641.00 | +2.40% |
| Beijing Luzhu Biotechnology Co., Ltd.SEHK: 2480 | $380.46M | HK$15.01 | +12.01% |
Figures last refreshed Oct 11, 2026.